MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series

BACKGROUND: Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRO...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauceri, Rodolfo, Coppini, Martina, Attanasio, Massimo, Bedogni, Alberto, Bettini, Giordana, Fusco, Vittorio, Giudice, Amerigo, Graziani, Filippo, Marcianò, Antonia, Nisi, Marco, Isola, Gaetano, Leonardi, Rosalia Maria, Oteri, Giacomo, Toro, Corrado, Campisi, Giuseppina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899375/
https://www.ncbi.nlm.nih.gov/pubmed/36739399
http://dx.doi.org/10.1186/s12903-023-02732-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899375/
https://www.ncbi.nlm.nih.gov/pubmed/36739399
http://dx.doi.org/10.1186/s12903-023-02732-6

Ejemplares similares